Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease

EuroIntervention. 2016 Aug 20;12(6):801-4. doi: 10.4244/EIJV12I6A130.
No abstract available

Publication types

  • Case Reports
  • Congress

MeSH terms

  • Absorbable Implants*
  • Antineoplastic Agents / administration & dosage
  • Blood Vessel Prosthesis Implantation*
  • Coronary Artery Disease / surgery*
  • Drug-Eluting Stents
  • Everolimus / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Tissue Scaffolds*

Substances

  • Antineoplastic Agents
  • Everolimus